Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Clinical trial NCT01101776 · COMPLETED
Trial details
- NCT number
- NCT01101776
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2010-01-01
- Primary completion
- 2013-04-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.